Engene Therapeutics Inc (ENGN)

Finanzdaten der Engene Therapeutics Inc-Aktie (ENGN)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-07-31	2026-04-30	2026-01-31	2025-10-31	2025-07-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
	6.40%34.01	31.97	31.19	39.48	29.95
Research and Development	9.48%20.09	22.20	22.26	31.72	22.58
Operating Income/Loss	6.40%-34.01	-31.97	-31.19	-39.48	-29.95
Nonoperating Income/Loss	13.10%1.51	1.74	1.43	1.10	1.20
Income/Loss From Continuing Operations Before Tax	7.52%-32.50	-30.23	-29.75	-38.38	-28.75
Income Tax Expense/Benefit	-	-	-	-0.50	0.24
	7.52%-32.50	-30.23	-29.75	-37.88	-28.99
Attributable To Parent	7.52%-32.50	-30.23	-29.75	-37.88	-28.99
Available To Common Stockholders, Basic	7.52%-32.50	-30.23	-29.75	-37.88	-28.99
Basic Average Shares	0.01%69.73	69.72	67.26	0.09	51.10
Diluted Average Shares	0.01%69.73	69.72	67.26	0.09	51.10
Basic Earnings Per Share	9.30%-0.47	-0.43	0.44	0.73	0.57
Diluted Earnings Per Share	9.30%-0.47	-0.43	0.44	0.73	0.57
Common Stock Dividends	-	-	-	-	-